CDKN2A and acute myeloid leukemia: By performing targeted bs-seq on 33 CHIP samples (21 control and 12 pre-AML), we found some patients with CHIP had hypermethylation at the p15 promoter (Fig. 3A) but not the p14 promoter (SI Appendix, Fig. S5A).